Loading...
Loading...
Opexa Therapeutics, Inc.
, a biopharmaceutical company
developing personalized immunotherapies for autoimmune disorders including
multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced the
issuance of four additional key patents covering its broad T-cell
immunotherapy platform. The recent allowances bring the number of granted
U.S. and international patents in Opexa's patent portfolio to 160, including
in-licensed patents. The expansion of Opexa's intellectual property
portfolio further strengthens the patent estate surrounding Tcelna(R),
Opexa's personalized T-cell immunotherapy in development for the treatment
of secondary progressive multiple sclerosis.
Recently-granted European Patent Nos. 1546719, 2016414 and 2420833 are
directed to Opexa's proprietary methods for preparing individualized T-cell
vaccines, while European Patent No. 2363710 is directed to the autologous
T-cell vaccine compositions themselves. The claims cover the use of
particular immunodominant epitopes found in myelin basic protein,
proteolipid protein and myelin oligodendrocyte protein in the preparation of
such T-cell vaccines, as well as the identification and use of specific
antigenic epitopes that are disease-relevant for individual patients from
these and other polypeptide antigens.
"We are very pleased with the issuance of the new European patents and the
continued growth of our intellectual property portfolio," stated Neil K.
Warma, President and Chief Executive Officer of Opexa. "This family of
patents is key to protecting and strengthening our intellectual property
position surrounding our personalized T-cell immunotherapy for the treatment
of autoimmune diseases. We continue to be aggressive in the strengthening of
our patent estate and have also recently submitted new patent applications
related to our proprietary epitope screening assay and potency assay."
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in